Investor Relations
Clerkenwell Health is a fast-growing clinical research organisation specialising in trials and pharmaceutical services for international developers of drugs used in psychedelic-assisted therapy.
Investment Highlights
Model
The only purpose-built psychedelic specialist clinical research organisation (CRO) in Europe.
Traction
Since launching in January 2021 we have signed multiple drug developers up for multi-phase clinical trials.
Team
Founders have worked together for over 5 years, achieving one successful exit already. Management have >30 years pharma and clinical trials experience.
Timing
Psychedelics gaining widespread acceptance from regulators. 50+ trials in-motion with FDA approving MDMA & psilocybin as ‘breakthrough therapies’.
Current Shareholders
Sign up to receive corporate updates from the Clerkenwell Health team in your inbox or speak to our team today.